Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 114

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 114
---
 as elsewhere in this prospectus, to better understand
the risks and uncertainties inherent in our business and underlying any forward-looking statements. As a result of these factors, we cannot
assure you that the forward-looking statements in this prospectus will prove to be accurate. Furthermore, if our forward-looking statements
prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements,
you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and
plans in any specified timeframe, or at all.

| 56 |

<div align='center'>THE COMMITTED EQUITY FINANCING</div>

Overview

On January 17, 2025, we entered
into the Purchase Agreement with the Selling Shareholder. Sales of our Depositary Shares to the Selling Shareholder under the Purchase
Agreement, and the timing of any sales, will be determined by us from time to time in our sole discretion and will depend on a variety
of factors, including, among other things, market conditions, the trading price of our Depositary Shares and determinations by us regarding
the use of proceeds from any sale of such Depositary Shares. The net proceeds from any sales under the Committed Equity Financing will
depend on the frequency with, and prices at, which the Depositary Shares are sold to the Selling Shareholder. To the extent we sell shares
under the Purchase Agreement, we currently plan to use the net proceeds to fund our development programs, for working capital and other
general corporate purposes. We cannot predict whether the net proceeds invested will yield a favorable return.

In accordance with our obligations
under the Purchase Agreement and the Registration Rights Agreement, dated as of January 17, 2025, between us and the Selling Shareholder,
or the Registration Rights Agreement, pursuant to which we agreed to provide the Selling Shareholder with customary registration rights
related to the shares issued under the Purchase Agreement, we have filed a registration statement of which this prospectus forms a part
in order to register the resale of up to: (i) 35,000,000 Purchase Shares that we may elect, in our sole discretion, to issue and sell
to the Selling Shareholder, from time to time after the Commencement Date upon the terms and subject to the conditions and limitations
of the Purchase Agreement (assuming the shares are sold at a price of $1.00 per share); and (ii) 875,000